Literature DB >> 2886856

Ursodeoxycholic acid for primary biliary cirrhosis.

A F Hofmann, H Popper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2886856     DOI： 10.1016/s0140-6736(87)92421-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

1.  New directions in primary biliary cirrhosis.

Authors:  M C Bateson
Journal:  BMJ       Date:  1990-12-08

2.  Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile.

Authors:  G Mazzella; P Fusaroli; A Pezzoli; F Azzaroli; C Mazzeo; L Zambonin; P Simoni; D Festi; E Roda
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

3.  The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids.

Authors:  T Higuchi; N Hishida; T Isomura; H Takeshima; H Hayashi
Journal:  Gastroenterol Jpn       Date:  1992-04

4.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

5.  Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.

Authors:  E Rolandi; R Franceschini; A Cataldi; V Cicchetti; L Carati; T Barreca
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 6.  Oral bile acids in cystic fibrosis-associated liver disease.

Authors:  C Colombo; A Crosignani; M G Apostolo; M T Marzano; N Bettinardi; A Giunta
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

Review 7.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

8.  Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia.

Authors:  G A Ramm; V G Nair; K R Bridle; R W Shepherd; D H Crawford
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

9.  Improved intestinal absorption of an enteric-coated sodium ursodeoxycholate formulation.

Authors:  A Roda; E Roda; E Marchi; P Simoni; C Cerrè; A Pistillo; C Polimeni
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

10.  Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat.

Authors:  P E Queneau; P Bertault-Peres; M Guitaoui; E Mesdjian; A Durand; J C Montet
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.